Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes
Open accessThe DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
Metformin has been designated as one of the most crucial first-line therapeutic agents in the management of type 2 diabetes mellitus. Primarily being an antihyperglycemic agent, metformin also has a plethora of pleiotropic effects on various systems and processes. It acts majorly by activating AMPK (Adenosine Monophosphate-Activated Protein Kinase) in the cells and reducing glucose output from the liver. It also decreases advanced glycation end products and reactive oxygen species production in the endothelium apart from regulating the glucose and lipid metabolism in the cardiomyocytes, hence minimizing the cardiovascular risks. Its anticancer, antiproliferative and apoptosis-inducing effects on malignant cells might prove instrumental in the malignancy of organs like the breast, kidney, brain, ovary, lung, and endometrium. Preclinical studies have also shown some evidence of metformin's neuroprotective role in Parkinson's disease, Alzheimer's disease, multiple sclerosis and Huntington's disease. Metformin exerts its pleiotropic effects through varied pathways of intracellular signalling and exact mechanism in the majority of them remains yet to be clearly defined. This article has extensively reviewed the therapeutic benefits of metformin and the details of its mechanism for a molecule of boon in various conditions like diabetes, prediabetes, obesity, polycystic ovarian disease, metabolic derangement in HIV, various cancers and aging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 2×
“In the same trial after 15-year follow-up, the mean annual occurrence of diabetes was 27% lower in patients assigned to lifestyle intervention and 18% lower in those randomized to metformin compared to placebo.(187) In 2022, the ADA (American Diabetes Association) recommended metformin therapy for adults with prediabe…”
BackgroundMethodWarburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 4×
“revealed by Zhou et al and they observed that it activated AMPK in rat hepatocytes at doses of 10 μM and 20 μM and provided a cellular basis for the drug’s blood glucose lowering action.(34) Cao et al demonstrated that modest dosages of metformin decreases glucose synthesis in primary hepatocytes without altering leve…”
BackgroundInfluentialSTATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383 · cited 1×
“can activate the STAT (“Signal Transducer and Activator of Transcription”) protein signalling pathway and can lead to raised survival, invasion, and cell proliferation in carcinoma cells while also guarding them against host immunity.(103)”
BackgroundTSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“Population studies indicate that metformin reduces the risk of developing cancer and death from cancer in diabetes people.(210,211)”
BackgroundGiovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
The mechanisms of action of metformin
Rena, G., Hardie, D. G., & Pearson, E. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4342-z · Cited by 2,287
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157 · cited 1×
“The decline in energy levels by diminished synthesis of ATP and resultant enhanced levels of AMP by increased activity of enzyme adenylate kinase is observed.(33) Evidence shows that metformin can even elevate AMP levels by blocking the activity of an enzyme named AMP deaminase that breaks down AMP.”
BackgroundDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
Wu, H., Esteve, E., Tremaroli, V., Khan, M. T., Caesar, R., Mannerås-Holm, L., Ståhlman, M., Olsson, L. M., Serino, M., Planas-Fèlix, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4345 · Cited by 1,632
-Synuclein in Parkinson's Disease
Stefanis, L. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009399 · Cited by 1,446
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368 · cited 3×
“It was rich in guanidine; later, many mono-guanidines (galegine) and diguanidines (synthalin) derivatives were developed.2 The toxicity profile of these medicines prevented them from achieving widespread recognition as antidiabetic medications, even though they considerably lowered the blood glucose level in animals.3…”
Background(2004) · doi:10.1016/s0092-8674(04)00452-0 · Cited by 1,356
Clinical pharmacokinetics of metformin
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318 · cited 3×
“It is rapidly distributed and does not bind with plasma protein.(9,14) Metformin clearance depends on renal function and declines in the presence of renal impairment.”
BackgroundMetformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X.-M., Braddock, D. T., Albright, R. A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., et al. (2014) · Nature · doi:10.1038/nature13270 · Cited by 1,284
Impact of intermittent fasting on health and disease processes
Mattson, M. P., Longo, V. D., & Harvie, M. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.10.005 · Cited by 1,187 · cited 1×
“Energy metabolism is crucial in maintaining sound neural health and it has been observed that any molecule or process that improves calorie management and decreases chances of hyperglycaemia like glucagon-like peptide-1, insulin-like GF1, and even caloric restriction has been observed to have neuroprotective effects.(…”
BackgroundForetz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181
Mechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052 · cited 1×
“Conventionally, it is quite established that metformin lowers blood glucose primarily by its action on the liver with a major effect by minimizing hepatic gluconeogenesis leading to curtailment in endogenous glucose production by the liver without a concomitant increase in plasma insulin concentrations.(25,26) Literat…”
BackgroundMetformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
Gut microbiota and intestinal FXR mediate the clinical benefits of metformin
Sun, L., Xie, C., Wang, G., Wu, Y., Wu, Q., Wang, X., Liu, J., Deng, Y., Xia, J., Chen, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0222-4 · Cited by 1,011
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880 · cited 2×
“IGF1R and MRP1 (“Multidrug Resistance-Associated Protein 1”) co-expression is linked to a poorer response to anticancer drugs.(130)”
BackgroundResultSahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861 · cited 2×
“Metformin was found to block the cell cycle in the “G(0)/G(1)” phase and this was observed with a sharp drop in the cyclin D1 levels, pRb phosphorylation, and elevated p27(kip) expression.(112,113,118) AMPK activation causes phosphorylation of distinctive sites on TSC (Tuberous sclerosis complex)-2 as well as inhibits…”
BackgroundObesity and cancer: the role of dysfunctional adipose tissue
van Kruijsdijk, R. C. M., van der Wall, E., & Visseren, F. L. J. (2009) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0372 · Cited by 715
Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers
American Diabetes Association (2022) · Clinical Diabetes · doi:10.2337/cd22-as01 · Cited by 664
Metformin-associated lactic acidosis: current perspectives on causes and risk
DeFronzo, R., Fleming, G. A., Chen, K., & Bicsak, T. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.10.014 · Cited by 658
De Felice, F. G., Vieira, M. N. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., Viola, K. L., Zhao, W.-Q., Ferreira, S. T., & Klein, W. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809158106 · Cited by 657
Evolutionary medicine: from dwarf model systems to healthy centenarians?
Longo, V. D., & Finch, C. E. (2003) · Science · doi:10.1126/science.1077991 · Cited by 575 · cited 1×
“Various levels of the IGF-1 pathway, including IGF-1 release from the liver or reduction in IGF-1 signalling, are affected by metformin.(275)”
BackgroundMetformin: An Old But Still the Best Treatment for Type 2 Diabetes
Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567 · cited 4×
“by reducing intestinal carbohydrate absorption and insulin resistance in addition to reducing ghrelin and leptin levels.(163,165) Different forms of cancers like rectum, pancreas, liver, and colon are observed to have a high incidence”
BackgroundInfluentialMetformin Inhibits Proinflammatory Responses and Nuclear Factor-κB in Human Vascular Wall Cells
Isoda, K., Young, J. L., Zirlik, A., MacFarlane, L. A., Tsuboi, N., Gerdes, N., Schönbeck, U., & Libby, P. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000201938.78044.75 · Cited by 499
The Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1299 · Cited by 494
Metformin Action: Concentrations Matter
He, L., & Wondisford, F. E. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.01.003 · Cited by 448 · cited 16×
“A biguanide known as metformin is a commonly recommended oral medicine for T2D.”
BackgroundMethodInfluentialKooy, A., de Jager, J., Lehert, P., Bets, D., Wulffelé, M. G., Donker, A. J. M., & Stehouwer, C. D. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.20 · Cited by 440
Hirsch, H. A., Iliopoulos, D., & Struhl, K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221055110 · Cited by 440 · cited 1×
“In several trials, the chemotherapeutic agent cisplatin was more harmful to melanoma cells when used with metformin.(260) These findings are interesting, but further research is required in this area.”
BackgroundMetformin: Mechanisms in Human Obesity and Weight Loss
Yerevanian, A., & Soukas, A. A. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00335-3 · Cited by 414 · cited 6×
“Metformin got included to the WHO’s essential medicines list in 2011.(3,4) Currently, metformin enjoys the status of the most often utilized anti-diabetic drug, either alone or in combination, in patients with type 2 diabetes mellitus (T2D).”
BackgroundInfluentialHowell, J. J., Hellberg, K., Turner, M., Talbott, G., Kolar, M. J., Ross, D. S., Hoxhaj, G., Saghatelian, A., Shaw, R. J., & Manning, B. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.12.009 · Cited by 408 · cited 1×
“This activation of AMPK can lead to subduing of mTORC1 (“Mammalian Target of Rapamycin Complex I”), which too can block the gluconeogenetic pathways.(60) The metformin-induced decreased gluconeogenesis from”
BackgroundMetformin induces unique biological and molecular responses in triple negative breast cancer cells
Liu, B., Fan, Z., Edgerton, S. M., Deng, X.-S., Alimova, I. N., Lind, S. E., & Thor, A. D. (2009) · Cell Cycle · doi:10.4161/cc.8.13.8814 · Cited by 392
Metformin reduces endogenous reactive oxygen species and associated DNA damage
Algire, C., Moiseeva, O., Deschênes-Simard, X., Amrein, L., Petruccelli, L., Birman, E., Viollet, B., Ferbeyre, G., & Pollak, M. N. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0536 · Cited by 372 · cited 1×
“complex I, hence leading to minimizing the synthesis of ROS ultimately leading to suppression of ROS-mediated DNA damage and the development of cancers.(129) Metformin has also proven beneficial in patients with diabetes receiving neoadjuvant chemotherapy.”
BackgroundHong, J., Zhang, Y., Lai, S., Lv, A., Su, Q., Dong, Y., Zhou, Z., Tang, W., Zhao, J., Cui, L., et al. (2013) · Diabetes Care · doi:10.2337/dc12-0719 · Cited by 366
Metformin in the Treatment of HIV Lipodystrophy Syndrome: A Randomized Controlled Trial
Hadigan, C., Corcoran, C., Basgoz, N., Davis, B., Sax, P., & Grinspoon, S. (2000) · JAMA · doi:10.1001/jama.284.4.472 · Cited by 357
Han, Y., Xie, H., Liu, Y., Gao, P., Yang, X., & Shen, Z. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0900-7 · Cited by 337 · cited 1×
“reported by a meta analysis where metformin reduced all-cause and cardiovascular death in patients having coronary artery illnesses.(76) The “MetCool ACS” trial has been initiated in patients without diabetes, to evaluate the effectiveness”
Long-Term Metformin Usage and Cognitive Function among Older Adults with Diabetes
Ng, T. P., Feng, L., Yap, K. B., Lee, T. S., Tan, C. H., & Winblad, B. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131901 · Cited by 334
Buse, J. B., DeFronzo, R. A., Rosenstock, J., Kim, T., Burns, C., Skare, S., Baron, A., & Fineman, M. (2016) · Diabetes Care · doi:10.2337/dc15-0488 · Cited by 325
Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase
Hunter, R. W., Hughey, C. C., Lantier, L., Sundelin, E. I., Peggie, M., Zeqiraj, E., Sicheri, F., Jessen, N., Wasserman, D. H., & Sakamoto, K. (2018) · Nature Medicine · doi:10.1038/s41591-018-0159-7 · Cited by 313 · cited 1×
“gluconeogenesis like fructose-1,6-bisphosphatase-1 and glycerol-3-phosphate dehydrogenase and enhancing glucose uptake by increased GLUT1 activity and IRS2 hence leading to reduction in plasma glucose levels.(29,61,62) Metformin also acts by varied”
BackgroundCampbell, J. M., Stephenson, M. D., de Courten, B., Chapman, I., Bellman, S. M., & Aromataris, E. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180263 · Cited by 292
Mohammed, I., Hollenberg, M. D., Ding, H., & Triggle, C. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.718942 · Cited by 278 · cited 1×
“the evidence from the majority of the clinical studies like MILES (Metformin In Longevity Study) and TAME (Targeting Aging with Metformin) seems to be controversial.(279,280) Data from the “Metformin to Augment Strength Training”
BackgroundPregnancy outcome after first-trimester exposure to metformin: a meta-analysis
Gilbert, C., Valois, M., & Koren, G. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.02.098 · Cited by 274
Emerging Wastewater Contaminant Metformin Causes Intersex and Reduced Fecundity in Fish
Niemuth, N. J., & Klaper, R. D. (2015) · Chemosphere · doi:10.1016/j.chemosphere.2015.03.060 · Cited by 262
Metformin attenuates Alzheimer’s disease-like neuropathology in obese, leptin-resistant mice
Li, J., Deng, J., Sheng, W., & Zuo, Z. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.03.002 · Cited by 260
Effects of metformin on weight loss: potential mechanisms
Malin, S. K., & Kashyap, S. R. (2014) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000095 · Cited by 223
Walton, R. G., Dungan, C. M., Long, D. E., Tuggle, S. C., Kosmac, K., Peck, B. D., Bush, H. M., Villasante Tezanos, A. G., McGwin, G., Windham, S. T., et al. (2019) · Aging Cell · doi:10.1111/acel.13039 · Cited by 210 · cited 1×
“Effective Response in Seniors (MASTERS) trial” reports that in healthy older adults, metformin impairs the hypertrophic muscle response to resistance training exercises, hence counteracting the benefits of physical activity.(281) These reports”
BackgroundMetformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth
Algire, C., Zakikhani, M., Blouin, M.-J., Shuai, J. H., & Pollak, M. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0038 · Cited by 185
Metformin suppresses intestinal polyp growth in Apc Min/+ mice
Tomimoto, A., Endo, H., Sugiyama, M., Fujisawa, T., Hosono, K., Takahashi, H., Nakajima, N., Nagashima, Y., Wada, K., Nakagama, H., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00933.x · Cited by 185 · cited 2×
“The mechanism behind the anticancer or growth-prohibiting effect of metformin in cancer cells can be ascribed to AMPK activation leading to different downstream impacts that work together to restrain the growth of tumors.(114,117) The AMPK-mediated downstream pathways for its anticancer activity majorly act through mT…”
BackgroundGlossmann, H. H., & Lutz, O. M. D. (2019) · Gerontology · doi:10.1159/000502257 · Cited by 149
Meng, S., Cao, J., He, Q., Xiong, L., Chang, E., Radovick, S., Wondisford, F. E., & He, L. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.604421 · Cited by 146 · cited 1×
“Meng et al, in their study on mouse-isolated hepatocytes, reported that a low concentration of metformin (25–100 μM) activated AMPK, whereas a higher concentration (500 μM) inhibited it.(51) Ravera et al studied the concentration-”
BackgroundMetformin and ageing: improving ageing outcomes beyond glycaemic control
Valencia, W. M., Palacio, A., Tamariz, L., & Florez, H. (2017) · Diabetologia · doi:10.1007/s00125-017-4349-5 · Cited by 142
Can Metformin Exert as an Active Drug on Endothelial Dysfunction in Diabetic Subjects
Salvatore, T., Pafundi, P. C., Galiero, R., Rinaldi, L., Caturano, A., Vetrano, E., Aprea, C., Albanese, G., Di Martino, A., Ricozzi, C., et al. (2020) · Biomedicines · doi:10.3390/biomedicines9010003 · Cited by 97
Subcellular Distribution of Metformin in Rat Liver
Wilcock, C., Wyre, N. D., & Bailey, C. J. (1991) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1991.tb03507.x · Cited by 86 · cited 1×
“modest and Wilcock et al observed that the distribution of metformin is majorly in the cytosol and only less than 10% enters mitochondria.(13,49,50) Meng et al, in their study on mouse-isolated hepatocytes, reported that a low concentration of metformin (25–100 μM) activated AMPK, whereas a higher concentration (500 μ…”
BackgroundMetformin-Treated Patients With Type 2 Diabetes Have Normal Mitochondrial Complex I Respiration
Larsen, S., Rabøl, R., Hansen, C. N., Madsbad, S., Helge, J. W., & Dela, F. (2012) · Diabetologia · doi:10.1007/s00125-011-2340-0 · Cited by 81 · cited 1×
“Though recent evidence does not favor metformin’s effect on complex I because the concentration needed to inhibit it is way higher than what is observed in the clinical use of this drug.(13,35) In support of this, a complex I inhibitor”
Metformin and Type 2 Diabetes Prevention
Aroda, V. R., & Ratner, R. E. (2018) · Diabetes Spectrum · doi:10.2337/ds18-0020 · Cited by 70
Metformin from mother to unborn child-are there unwarranted effects?
Nguyen, L., Chan, S.-Y., & Teo, A. K. K. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.047 · Cited by 67
Steady-State Pharmacokinetics of Metformin Is Independent of the OCT1 Genotype in Healthy Volunteers
Christensen, M. M. H., Højlund, K., Hother-Nielsen, O., Stage, T. B., Damkier, P., Beck-Nielsen, H., & Brøsen, K. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1853-8 · Cited by 62
Hou, Y.-C., Hu, Q., Huang, J., Fang, J.-Y., & Xiong, H. (2017) · Oncotarget · doi:10.18632/oncotarget.13633 · Cited by 29
Gao, L., Huang, H., Zhang, L., Zhang, N., Fu, Y., Zhu, D., Bi, Y., & Feng, W. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1608-0345 · Cited by 24 · cited 2×
“However, when compared with other drugs used in diabetes, molecules like GLP-1 analogues have superior efficacy in reducing weight as compared to metformin.(196,199)”
Background
Metadata
- Authors
- Dutta, S., Shah, R. B., Singhal, S., Dutta, S. B., Bansal, S., Sinha, S., & Haque, M.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2023-06
- Volume
- Volume 17
- Pages
- 1907-1932
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W4381987886
- Cited by
- 248
- References
- 75
- FWCI
- 18.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.